Evaluating heart health risks after breast cancer radiotherapy
Official title: Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer - a Prospective Longitudinal Study
Run by St. Olavs Hospital · NCT02541435 · Data updated 2026-11-12
This study is trying to see if newer radiotherapy techniques for breast cancer can lower the risk of heart problems compared to traditional methods in patients over 15 years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 30 Years to 70 Years |
| Sex | Women only |
| Enrollment | 1600 (estimated) |
| Sponsor | St. Olavs Hospital Academic / other |
| Drugs / interventions | trastuzumab, radiation |
| Locations | 2 sites (Ålesund and 1 other locations) |
| Status | Recruiting |
| Started | November 2016 |
| Main results expected | December 2029 |
| Study ends | December 2036 |
| Registry record updated | June 4, 2026 |
| Trial ID | NCT02541435 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women diagnosed with breast cancer who have an expected life expectancy of over 10 years.
✕Probably not a fit
Patients who are unwilling to participate in the study will not benefit from its findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the incidence and prevalence of cardiovascular diseases in breast cancer patients who have undergone different radiotherapy techniques. It will compare outcomes between patients treated with conventional radiotherapy and those treated with newer laser-assisted breath-controlled radiotherapy. The study will follow these two cohorts over a period of 15 years to determine if advancements in radiotherapy reduce the risk of cardiovascular complications. The research will utilize various imaging techniques to monitor heart health over time.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols that minimize cardiovascular risks for breast cancer survivors.
How similar studies have gone: While there have been studies on cardiovascular risks associated with breast cancer treatments, this specific comparison of newer radiotherapy techniques is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of breast cancer * expected life-expectancy above 10 years Exclusion Criteria: * Not willing to participate
Where it's running
-
Ålesund Hospital
Ålesund, Norway Recruiting -
St Olavs University Hospital
Trondheim, Norway Recruiting
Study contacts
- Study coordinator: torgeir wethal, md phd
- Email: torgeir.wethal@stolav.no
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based prediction of five major diseases using integrated health data
Researchers are testing an AI model to see if they can predict the onset of five major diseases in adults 30–65 by combining medical records with biospecimens and lifestyle data.
-
Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors
This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.
-
Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery
This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
Breast cancer subtypes and outcomes in Colombian women
This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.
-
Colchicine for preventing cardiovascular disease in adults with type 2 diabetes
A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.